Ceapro Inc CRPOF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRPOF is a good fit for your portfolio.
News
-
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
-
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
-
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
-
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
-
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
-
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
-
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
-
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
Trading Information
- Previous Close Price
- $0.18
- Day Range
- $0.18–0.18
- 52-Week Range
- $0.12–0.44
- Bid/Ask
- $0.15 / $0.19
- Market Cap
- $13.87 Mil
- Volume/Avg
- 6,451 / 22,204
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.66
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ceapro Inc is engaged in the development and marketing of various health and wellness products and technology relating to plant extracts. Its operating segment is the active ingredient product technology industry which involves the development of proprietary extraction technologies and the application of these technologies to the production and development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. Active ingredients produced include oat beta glucan and avenanthramides. The group derives revenue from the U.S., Germany, China, Canada and other countries, of which prime revenue is generated from the U.S.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- https://www.ceapro.com
Valuation
Metric
|
CRPOF
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.63 |
Price/Sales | 1.66 |
Price/Cash Flow | — |
Price/Earnings
CRPOF
Financial Strength
Metric
|
CRPOF
|
---|---|
Quick Ratio | 7.59 |
Current Ratio | 11.00 |
Interest Coverage | −26.19 |
Quick Ratio
CRPOF
Profitability
Metric
|
CRPOF
|
---|---|
Return on Assets (Normalized) | −7.31% |
Return on Equity (Normalized) | −8.31% |
Return on Invested Capital (Normalized) | −7.40% |
Return on Assets
CRPOF
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lpjqtcdb | Vgth | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Djfjjdvjp | Tsgtch | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pgzfdhzm | Rpgjrkr | $98.1 Bil | |
MRNA
| Moderna Inc | Gwqnbkp | Jscf | $39.1 Bil | |
ARGX
| argenx SE ADR | Ghfwxpzj | Dvw | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Rqbdcsqf | Wnns | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xvfhdjft | Lcwltl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bnwhklbdg | Xmvspqg | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qhsphbkxjf | Htynk | $12.5 Bil | |
INCY
| Incyte Corp | Tmyvqzhvf | Tqrlxj | $11.9 Bil |